Treatment for calcification issues in Fahr's disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of bisphosphonates, specifically etidronate, in treating patients diagnosed with Fahr's disease or syndrome, which is characterized by calcifications in the brain. The study aims to assess the impact of this treatment on the neuropsychiatric and cognitive symptoms associated with the condition. Participants will be randomly assigned to receive either etidronate or a placebo, with their progress monitored over the course of the trial. The goal is to provide a potential disease-modifying therapy for a condition that currently lacks effective treatments.

Why it matters

Who can join: the full rules

Inclusion criteria are:

1. Age of 18 years or over,
2. Clinical diagnosis of Fahr's disease or syndrome. No international accepted diagnostic criteria for Fahr's disease or syndrome exist yet. It is diagnosed mostly based on the clinical presentation. For the present study the following criteria are used:

   1. Clinical symptoms consistent with a clinical diagnosis of Fahr's disease or syndrome.
   2. Bilateral calcifications of the basal ganglia as seen on the computed tomography (CT) scan of the head. To rule out basal ganglia calcifications due to aging, a CT based calcification score will be used as proposed by Nicolas et al. Calcification is graded from 0 (no calcification) to 5 (serious and confluent) in specific locations of the brain; lenticular, caudate, thalamus nuclei, subcortical white matter, cortex, cerebellar hemispheres, vermis, midbrain, pons, and medulla. The total calcification score (ranging from 0 to 80) is obtained by adding all location-specific points, where a score higher than the age-specific threshold points at Fahr's disease or syndrome.

      Furthermore, the next criteria are supportive for the clinical diagnosis of PFBC:
   3. Frequently, the family history is consistent with autosomal dominant inheritance. A positive family history with at least one relative in the first or second degree with symptoms of PFBC is supportive for the clinical diagnosis of PFBC.
   4. The presence of a (likely) pathogenic mutation in one of the PFBC-related genes is supportive for the clinical diagnosis of PFBC. Mutations in up to now 4 known genes are associated with an autosomal dominant pattern of inheritance: solute carrier family 20 member 2 (SLC20A2) (OMIM#213600), xenotropic and polytropic retrovirus receptor 1 (XPR1) (OMIM#616413), platelet-derived growth factor b (PDGFB) (OMIM#615483), and platelet-derived growth factor receptor b (PDGFRB) (OMIM#615007). Autosomal recessively inherited PFBC is associated with mutations in two genes: myogenesis-regulating glycosidase (MYORG) (OMIM#618317) and junctional adhesion molecule 2 (JAM2) (OMIM#618824).

Exclusion criteria are:

1. unable or unwilling to sign an informed consent,
2. severe renal impairment (estimated glomerular filtration rate (eGFR) of \<30 ml/min/1.73m2 calculated using CKD-EPI equation),
3. contraindication to receiving oral medication (for example severe dysphagia),
4. known abnormality of the oesophagus that would interfere with the passage of the drug (for example oesophageal strictures or achalasia),
5. known sensitivity to etidronate,
6. pregnancy, women with an active pregnancy wish \<1 year, or women who are breastfeeding at the time of inclusion,
7. inability to undergo a Dutch neuropsychological assessment (for example, non-fluent Dutch speakers or severe visual, hearing or motor impairment),
8. any other medical or social condition that puts the subject at risk of harm during the study or might adversely affect the interpretation of the study data,
9. use of bisphosphonates during the last 5 years,
10. hypocalcaemia (calcium \<2.20 mmol/L),
11. 25-OH vitamin D deficiency \<35 nmol/L. After correction of hypocalcaemia or vitamin D deficiency, a participant is again suitable for participation.

Where it's running

• University Medical Center Utrecht
  Utrecht, Utrecht, Netherlands Recruiting
• University College London Hospital
  London, United Kingdom Not yet recruiting

Study contacts

• Principal investigator: Huiberdina L Koek, MD, PhD — UMC Utrecht
• Study coordinator: Huiberdina L Koek, MD PhD
• Email: h.l.koek@umcutrecht.nl
• Phone: 0031 88 75 55555

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cardiac risk test using breast cancer radiotherapy scans to guide decisions

  This study tests whether checking coronary artery calcium on planning CT scans can help patients with breast cancer make informed heart-risk decisions during radiotherapy planning.

  Recruiting UMC Utrecht · Copenhagen and 4 other locations · NCT07703033

• Cannabidiol as add-on therapy for children with refractory epilepsy (CBD-uN1que): an individualized N-of-1 series

  This trial tests whether CBD oil helps reduce seizures in children with hard-to-treat epilepsy, using a series of personalized N-of-1 comparisons against a placebo.

  Recruiting Phase 3 UMC Utrecht · Utrecht, Utrecht · NCT07668856

• Brain-Computer Interface to Control Digital Devices for People with High Cervical Spinal Cord Injury

  This study tests a fully implantable brain-computer interface to let people with high cervical spinal cord injuries control digital devices at home.

  Recruiting UMC Utrecht · Utrecht, Utrecht · NCT07640711

• Multicenter registry for adults with spontaneous subarachnoid hemorrhage

  This project collects detailed information from adults who had a spontaneous subarachnoid hemorrhage to see which treatments and care patterns lead to better outcomes.

  Recruiting at 9 sites UMC Utrecht · Nijmegen, Gelderland and 8 other locations · NCT07482124

• Right-time self-care advice for hip and knee osteoarthritis (e-cOAch)

  This project will test whether an online program can use regular symptom and activity reports to predict and deliver the right self-care advice about physical activity, weight, or sleep for people with hip or knee osteoarthritis.

  Recruiting UMC Utrecht · Utrecht · NCT07423858

• Chemotherapy plus adaptive MR-guided radiotherapy for esophageal adenocarcinoma

  This Phase 1 trial will see if adding adaptive MR-guided radiotherapy to perioperative chemotherapy (FLOT) before surgery helps adults with resectable esophageal or gastroesophageal junction adenocarcinoma.

  Recruiting Phase 1 UMC Utrecht · Utrecht, Utrecht · NCT07359443

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.